Telix Pharmaceuticals Ltd income statement

In fiscal 2025, Telix Pharmaceuticals Ltd reported revenue of $804m, up 55.6% on the year before, operating income of $29.8m (a 3.7% margin) and net income of −$7.1m, or −$0.02 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Telix Pharmaceuticals Ltd: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	333	517	804
Cost of revenue	123	180	377
Gross profit	210	336	426
Research and development	85	128	171
Operating income	11	55	30
Interest expense	0	0	0
Income before tax	3	38	−5
Income tax	−2	4	2
Net income	4	34	−7
Diluted EPS	$0.01	$0.10	−$0.02
Diluted shares (average)	324m	345m	338m
EBITDA	15	60	51

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: TGTX vs TLX ASND vs TLX IONS vs TLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Telix Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Telix Pharmaceuticals Ltd.